Get the Stockscreener App
211.94
1.88%
2.53
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $211.94, with a volume of 96,531.
It is up +1.88% in the last 24 hours and up +7.88% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$209.41
Open:
$210.95
24h Volume:
96,531
Relative Volume:
0.11
Market Cap:
$23.52B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
23.38
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+2.84%
1M Performance:
+7.88%
6M Performance:
+12.59%
1Y Performance:
+26.85%
1-Day Range:
$209.96
$214.40
1-Week Range:
$201.00
$214.40
52-Week Range:
$165.30
$219.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
212.48 | 23.18B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
535.96 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.91 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.82 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
133.84 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
266.61 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends - ad-hoc-news.de
Is Quest Diagnostics Inc (DGX) Overvalued After 3.8% Rally? GF V - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
A 9-Day Losing Streak Has Quest Diagnostics Stock Down 6.2% - Trefis
Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth - ad-hoc-news.de
Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating - marketscreener.com
Quest Diagnostics Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since September 2001 -- Data Talk - Moomoo
A4ET8Q Bond Profile — Key Metrics - TradingView
A28XES Bond Risk Profile - TradingView
US74834LBB53 Bond Coupon Profile — Rate & Payments - TradingView
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus - TradingView
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD) - The Globe and Mail
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $245 - Moomoo
Quest Diagnostics stock holds steady as diagnostics demand supports long-term growth - ad-hoc-news.de
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
Quest Diagnostics (DGX) Proxy filing Summary - Quartr
Quest Diagnostics (DGX) Q4 2025 earnings summary - Quartr
Marijuana drives half of 2025 worker hair drug positives as fentanyl rates fall - Stock Titan
Quest Diagnostics stock stays supported by steady diagnostics demand - ad-hoc-news.de
Quest Diagnostics steadies its business model as demand for testing evolves - Ad-hoc-news.de
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics updates digital tools as testing demand evolves - Ad-hoc-news.de
Quest Diagnostics Incorporated Integrates Oncology Test Access with Flatiron Health Oncoemr for American Oncology Network - marketscreener.com
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI - marketscreener.com
Quest Diagnostics brings cancer test ordering into OncoEMR for 4,700 clinicians - Stock Titan
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Quest Diagnostics highlights its diagnostics role as investors assess the health services sector - ad-hoc-news.de
Quest Diagnostics stock steady as investors await the next catalyst - Ad-hoc-news.de
Quest Diagnostics Quantiferon-TB Gold Pluslab test quietly underpins US tuberculosis screening - ad-hoc-news.de
Quest Diagnostics highlights long-term testing role in U.S. healthcare - ad-hoc-news.de
DGXQuest Diagnostics Inc Volatility & Greeks - Finviz
Quest Diagnostics Incorporated (DGX) hits fresh high: Is there still room to run? - MSN
If You Invested $1,000 in Quest Diagnostics Inc (DGX) - Stock Titan
Quest Diagnostics outlines its role in medical testing as investors weigh long-term demand - ad-hoc-news.de
Quest Diagnostics highlights its role in US healthcare. The stock reflects a stable diagnostics busi - Ad Hoc News
Director Timothy Wentworth receives 144 DGX phantom units as deferred pay - Stock Titan
Quest Diagnostics steadies after recent volatility as investors focus on core testing business - ad-hoc-news.de
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Fund Update: 111,974 QUEST DIAGNOSTICS (DGX) shares added to EASTERN BANK portfolio - Quiver Quantitative
Quest Diagnostics's Q2 2026 Earnings: What to Expect - inkl
Quest Diagnostics (DGX) Q1 2025 earnings summary - Quartr
Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE - Ad-hoc-news.de
Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX - TradingView
Quest Diagnostics highlights long-term strategy, shares hold near recent highs - ad-hoc-news.de
ETFs Investing in Quest Diagnostics Incorporated Stocks - TradingView
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Incorporated Actuals & Estimates (NYSE:DGX) - TradingView
Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs - Morningstar
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.86%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):